Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4

被引:55
作者
Cedervall, Peder [1 ]
Aulabaugh, Ann [1 ]
Geoghegan, Kieran F. [1 ]
McLellan, Thomas J. [1 ]
Pandit, Jayvardhan [1 ]
机构
[1] Pfizer Inc, Worldwide Res & Dev, Struct Biol & Biophys Grp, Groton, CT 06340 USA
关键词
PDE4; cAMP hydrolysis; acrodysostosis; UCR1/2; phosphodiesterase regulation; CAMP-SPECIFIC PHOSPHODIESTERASE; AMP-SPECIFIC PHOSPHODIESTERASES; CONSERVED REGIONS UCRS; CYCLIC-AMP; PROTEIN-KINASE; MAP KINASE; MUTATIONS; ROLIPRAM; ACRODYSOSTOSIS; PHOSPHORYLATION;
D O I
10.1073/pnas.1419906112
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Phosphodiesterase 4 (PDE4) is an essential contributor to intracellular signaling and an important drug target. The four members of this enzyme family (PDE4A to -D) are functional dimers in which each subunit contains two upstream conserved regions (UCR), UCR1 and -2, which precede the C-terminal catalytic domain. Alternative promoters, transcriptional start sites, and mRNA splicing lead to the existence of over 25 variants of PDE4, broadly classified as long, short, and supershort forms. We report the X-ray crystal structure of long form PDE4B containing UCR1, UCR2, and the catalytic domain, crystallized as a dimer in which a disulfide bond cross-links cysteines engineered into UCR2 and the catalytic domain. Biochemical and mass spectrometric analyses showed that the UCR2-catalytic domain interaction occurs in trans, and established that this interaction regulates the catalytic activity of PDE4. By elucidating the key structural determinants of dimerization, we show that only long forms of PDE4 can be regulated by this mechanism. The results also provide a structural basis for the long-standing observation of high-and low-affinity binding sites for the prototypic inhibitor rolipram.
引用
收藏
页码:E1414 / E1422
页数:9
相关论文
共 49 条
  • [11] Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
    de Rooij, J
    Zwartkruis, FJT
    Verheijen, MHG
    Cool, RH
    Nijman, SMB
    Wittinghofer, A
    Bos, JL
    [J]. NATURE, 1998, 396 (6710) : 474 - 477
  • [12] Features and development of Coot
    Emsley, P.
    Lohkamp, B.
    Scott, W. G.
    Cowtan, K.
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2010, 66 : 486 - 501
  • [13] Structural basis for the design of selective phosphodiesterase 4B inhibitors
    Fox, David, III
    Burgin, Alex B.
    Gurney, Mark E.
    [J]. CELLULAR SIGNALLING, 2014, 26 (03) : 657 - 663
  • [14] Francis SH, 2011, HANDB EXP PHARMACOL, V204, P47, DOI [10.1007/978-3-642-17969-3_2, 10.1007/978-3-642-13443-2_4]
  • [15] The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579
    Hoffmann, R
    Baillie, GS
    MacKenzie, SJ
    Yarwood, SJ
    Houslay, MD
    [J]. EMBO JOURNAL, 1999, 18 (04) : 893 - 903
  • [16] Phosphodiesterase-4 as a therapeutic target
    Houslay, MD
    Schafer, P
    Zhang, KYJ
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (22) : 1503 - 1519
  • [17] PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization
    Houslay, MD
    Adams, DR
    [J]. BIOCHEMICAL JOURNAL, 2003, 370 : 1 - 18
  • [18] Putting the lid on phosphodiesterase 4
    Houslay, Miles D.
    Adams, David R.
    [J]. NATURE BIOTECHNOLOGY, 2010, 28 (01) : 38 - 40
  • [19] The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram
    Huston, E
    Pooley, L
    Julien, P
    Scotland, G
    McPhee, I
    Sullivan, M
    Bolger, G
    Houslay, MD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (49) : 31334 - 31344
  • [20] Jacobitz S, 1996, MOL PHARMACOL, V50, P891